Home⇛Science Asia Review⇛vol. 12 no. 1 (2025)

Repurposing Anti-Hypertensive Agents For The Treatment Of Parkinson’S Disease: A Review

Fatimae Ituralde Mariano | Erwin Martinez Faller

Discipline: medicine (non-specific)

 

Abstract:

Parkinson's disease (PD) is the most prevalent neurological movement disorder, with an annual incidence of 5 to 35 cases per 100,000 population and a prevalence that ranges from 1% of adults aged 45-54 to 4% of males over the age of 85. Neurological illnesses are often regarded as the primary cause of disability. Parkinson's disease (PD) is the world's second most common neurological illness, after only Alzheimer's disease, and has been on the rise in recent years. Parkinson's disease is a condition that drastically impacts one's motor abilities and daily life. Characteristics include bradykinesia, stiffness, tremors when at rest, and loss of postural stability leading to gait issues. Moreover, non-motor aspects such as disrupted sleep, cognitive declines, depression, problems with autonomic functions, and reduced sense of smell compound the severity of the disease. While dopamine replacement aims to reinstate dopaminergic signaling to regulate movement abnormalities, non-motor burdens continue draining those with Parkinson's disease. Despite medical intervention, living with both motor and non-motor challenges intensifies the experience of Parkinson's disease each passing day. Despite breakthroughs in understanding Parkinson's disease, existing medications are symptomatic but do not stop the illness's development. Furthermore, medicines used to treat Parkinson's disease cause side effects that can be severe and devastating, such as dyskinesias. As a result, drug discovery approaches that offer more effective and safer therapeutic options are required. In addition to these initiatives, medication repurposing has been used, which lowers costs and research timelines as compared to the usual de novo drug development techniques. In this study, we will examine why there is interest in repurposing medications approved for hypertension therapy as neuroprotective choices.



References:

  1. Athauda D, Foltynie T. Drug repurposing in Parkinson’s disease. CNS Drugs. 2018;32(8):747–761. doi: 10.1007/s40263-018-0548-y.
  2. Becker Claudia, Jick Susan, and Meier, Christoph. Use of antihypertensives and the risk of Parkinson disease. Neurology. Volume 70. 16 part 2. Pages 1438-1444. 2008. doi: 10.1212/01.wnl.0000303818.38960.44
  3. Chen X, Gumina G, Virga KG. Recent Advances in drug repurposing for Parkinson’s disease. Curr Med Chem. 2018;26(28):5340–5362. doi: 10.2174/0929867325666180719144850.
  4. Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson’s disease: implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020;134(104700):1–18.
  5. Contaldi, Elena MD1,2,*; Magistrelli, Luca1,3; Milner, Anna V.1; Cosentino, Marco4,5; Marino, Franca4,5; Comi, Cristoforo1,4. Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study. Neural Regeneration Research, 16(12):p 2475-2478, December 2021. | DOI: 10.4103/1673-5374.313061
  6. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877–97. doi: 10.1016/S1474-4422(17)30299-5.
  7. Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795–803. doi: 10.1136/jnnp-2019-322338.
  8. Jefri M., Bell S., Peng H., Hettige N., Maussion G., Soubannier V., Wu H., Silveira H., Theroux J.-F., Moquin L., et al. Stimulation of L-type calcium channels increases tyrosine hydroxylase and dopamine in ventral midbrain cells induced from somatic cells. Stem Cells Transl. Med. 2020;9:697–712. doi: 10.1002/sctm.18-0180.
  9. Jo Y, Kim S, Ye BS, Lee E, Yu YM. Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson's Disease: A Nationwide Cohort Study. Front Pharmacol. 2022 Mar 3;13:837890. doi: 10.3389/fphar.2022.837890.
  10. Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS. Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study. PLoS One. 2014 Jun 9;9(6):e98961. doi: 10.1371/journal.pone.0098961.
  11. Lin HC, Tseng YF, Shen AL, Chao JC, Hsu CY, Lin HL. Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension: A Retrospective Cohort Study. Am J Med. 2022 Aug;135(8):1001-1007. doi: 10.1016/j.amjmed.2022.04.029.
  12. Locatelli A., Cosconati S., Micucci M., Leoni A., Marinelli L., Bedini A., Ioan P., Spampinato S.M., Novellino E., Chiarini A., et al. Ligand based approach to L-type calcium channel by imidazo [2,1-b]thiazole-1,4-dihydropyridines: From heart activity to brain affinity. J. Med. Chem. 2013;56:3866–3877. doi: 10.1021/jm301839q.
  13. Marsot A, Guilhaumou R, Azulay JP, Blin O. Levodopa in Parkinson’s disease: a review of population pharmacokinetics/pharmacodynamics analysis. J Pharm Pharm Sci. 2017;20:226–238. doi: 10.18433/J30H04.
  14. National Institute of Neurological Disorders and Stroke. Parkinson’s Disease: Hope Through Research. Bethesda, Maryland; 2020. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Parkinsons-Disease-Hope-Through-Research.
  15. Parisi D, Adasme MF, Sveshnikova A, Bolz SN, Moreau Y, Schroeder M. Drug repositioning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs. Comput Struct Biotechnol J.
  16. Pasternak B, Svanström H, Nielsen N, Fugger L, Melbye M, Hviid A. Use of Calcium Channel Blockers and Parkinson’s Disease. American Journal of Epidemiology, 175(7), 627–635. https://doi.org/10.1093/aje/kwr362
  17. Politi C, Ciccacci C, Novelli G, Borgiani P. Genetics and treatment response in Parkinson’s disease: an update on pharmacogenetic studies. NeuroMolecular Med. 2018;20(1):1–17. doi: 10.1007/s12017-017-8473-7.
  18. Reardon KA, Mendelsohn FA, Chai SY, Horne MK. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust N Z J Med. 2000 Feb;30(1):48-53. doi: 10.1111/j.1445-5994.2000.tb01054.x.
  19. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010 May;67(5):600-6. doi: 10.1002/ana.21937.
  20. Saavedra JM, Sánchez-Lemus E, Benicky J. Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology. 2011;36:1–18.
  21. Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial. JAMA Neurol. 2017;74(2):216–224. doi: 10.1001/jamaneurol.2016.4467.
  22. Schrag A., Bohlken J., Dammertz L., Teipel S., Hermann W., Akmatov M.K., et al. Widening the spectrum of risk factors, comorbidities, and prodromal features of Parkinson disease. JAMA Neurol. (2022), 10.1001/jamaneurol.2022.3902
  23. Simon, D.K.; Tanner, C.M.; Brundin, P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin. Geriatr. Med. 2020, 36, 1–12.
  24. Sonsalla PK, Coleman C, Wong LY, Harris SL, Richardson JR, Gadad BS, Li W, German DC. The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism. Exp Neurol. 2013 Dec;250:376-83. doi: 10.1016/j.expneurol.2013.10.014.
  25. Tseng Yuan-Fu, Lin Hsiu-Chen, Chao Jane Chen-Jui, C Hsu hien-Yeh, Lin Hsiu-Li. Calcium Channel blockers are associated with reduced risk of Parkinson's disease in patients with hypertension: A population-based retrospective cohort study. Journal of the Neurological Sciences, Volume 424, 2021, 117412, ISSN 0022-510X, https://doi.org/10.1016/j.jns.2021.117412.
  26. Tulbă, D.; Avasilichioaiei, M.; Dima, N.; Crăciun, L.; Bălănescu, P.; Buzea, A.; Băicuș, C.; Popescu, B.O. Shared Molecular Targets in Parkinson’s Disease and Arterial Hypertension: A Systematic Review. Biomedicines 2022, 10, 653. https://doi.org/10.3390/biomedicines10030653
  27. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-905. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1. PMID: 28150045.
  28. Unger T., Borghi C., Charchar F., Khan N.A., Poulter N.R., Prabhakaran D., et al. International society of hypertension global hypertension practice guidelines. Hypertension (Dallas, Tex : 1979), 75 (2020), pp. 1334-1357, 10.1161/HYPERTENSIONAHA.120.15026

Tools


Copyright © 2025  KITE Digital Educational Solutions |  Exclusively distributed by CE-Logic